Citicoline as Neuroprotector in Neonates Exposed to Hypoxia

Neonatal Hypoxia Clinical Trial

Official title:

Efficacy of Citicoline as Neuroprotector in Neonates Exposed to Hypoxia: A Randomized Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03949049
• Other study ID #: neonates tanta
• Status: Recruiting
• Phase: Phase 3
• Start date: February 1, 2019
• Est. completion date: December 1, 2029

Study information

• Verified date: May 2019
• Source: Tanta University
• Contact: sherief abd-elsalam, ass. prof.
• Phone: 00201147773440
• Email: sheriefabdelsalam[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Citicoline as neuroprotector in neonates exposed to hypoxia: A randomized controlled trial

Description:

Efficacy of Citicoline as neuroprotector in neonates exposed to hypoxia: A randomized controlled trial

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: December 1, 2029
• Est. primary completion date: December 1, 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 1 Month

Eligibility

Inclusion Criteria:

• neonates with hypoxia.

Exclusion Criteria:

• hypoxic ischemic encephalopathy

Related Conditions & MeSH terms

• Hypoxia
• Neonatal Hypoxia

Intervention

Drug:
• Citicoline
Citacoline as neuroprotector

Other:
• Placebo
placebo group

Locations

Country	Name	City	State
Egypt	Sherief Abd-Elsalam	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Sherief Abd-Elsalam

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of seizures		6 months